Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 16, 2008

View Archived Issues

Novel agents for asthma and other respiratory disorders reported in recent patents

Enhanced effects seen with combination of radiotherapy and AZD-6244 in lung cancer model

Experiments with caprospinol reveal potentially useful effects against Alzheimer's disease

Arete describes new antihypertensive agents in a recent patent

Recent GSK, Ranbaxy and Schering patents disclose novel antimicrobial agents

Beneficial effects of iNOS inhibitors demonstrated in experimental COPD

URL submits NDA to the FDA for colchicine tablets in gout flares

MJFF awards USD 2 million grant to research projects on cognitive deficits in PD

FDA to review Arpida's NDA for iclaprim in cSSSI in November 2008

Synta receives USD 25 million milestone payment from GSK under elesclomol collaboration

RXi licenses rights from UMMS to technology for oral delivery of RNAi therapeutics

Lilly initiates cash tender offer for ImClone at USD 70 per share

Aradigm completes enrollment in phase II study of inhaled liposomal ciprofloxacin

Regado completes enrollment in REVERSAL-PCI phase IIa clinical study of REG1

Inhibiting FtsZ protein shows potential anti-staphylococcal activity in experimental model

Addex completes the first part of a two-part phase I ADX-48621 trial

Akorn launches Akten Gel 3.5% as a topical ocular anesthetic

Almirall and Forest to progress the development of aclidinium bromide

Avigen initiates exploratory study of AV-411 in opioid withdrawal

ChemoCentryx advances oral CCR9 antagonist CCX-025 into the clinic

BioMarin presents phase IIa results for 6R-BH4 in sickle cell disease

Palifosfamide receives positive opinion for E.U. orphan product designation

Sirion launches Durezol for postoperative ocular inflammation and pain

R&D highlights from the UBS Global Life Sciences Conference in New York: Oxford BioMedica

Lapatinib shows encouraging activity in phase II SCCHN study

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 12, 2026.
Europe’s Alzecure, Orionis in $1B+ deals with Lilly, Novartis
BioWorld
Two companies with European ties signed billion-dollar deals with large pharma firms in the last two days to discover and develop molecular glue drugs, as well as...
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...
Sanofi phase III CIDP quit dents Dianthus; C1 mismatch?
BioWorld
Investors in Dianthus Therapeutics Inc. apparently chose to ignore subtleties in the difference between efforts with that firm’s claseprubart vs. those by...
Microbiota modulates the antidepressant effects of GLP-1 analogues
BioWorld Science
Liraglutide, a glucagon-like peptide 1 (GLP-1) receptor agonist used in diabetes and obesity, could alleviate depression through a pathway that does not depend on...